<!doctype html>
<html lang="en">
  <head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Arrhythmias - Clinical Study Note</title>
    <link rel="icon" type="image/png" sizes="48x48" href="/icons/favicon-48.png?v=20260227-favicon1" />
    <link rel="icon" type="image/png" sizes="32x32" href="/icons/favicon-32.png?v=20260227-favicon1" />
    <link rel="icon" type="image/png" sizes="16x16" href="/icons/favicon-16.png?v=20260227-favicon1" />
    <link rel="apple-touch-icon" sizes="180x180" href="/icons/favicon-180.png?v=20260227-favicon1" />
    <style>
      :root {
        --bg: #f8fbff;
        --surface: #ffffff;
        --ink: #12243c;
        --muted: #54677d;
        --line: #d7e3f0;
        --brand: #7a1f1f;
        --brand-soft: #fff0ef;
        --teal-soft: #eefbf8;
        --warn-soft: #fff6e8;
        --danger-soft: #fff0f0;
      }

      * {
        box-sizing: border-box;
      }

      body {
        margin: 0;
        font-family: "Segoe UI", Tahoma, Arial, sans-serif;
        color: var(--ink);
        background:
          radial-gradient(circle at 84% 6%, #ffd8d4 0%, transparent 30%),
          radial-gradient(circle at 7% 22%, #dff6ff 0%, transparent 24%),
          var(--bg);
      }

      .wrap {
        width: min(1240px, 94vw);
        margin: 22px auto 34px;
        display: grid;
        grid-template-columns: 290px 1fr;
        gap: 16px;
      }

      .panel {
        background: var(--surface);
        border: 1px solid var(--line);
        border-radius: 16px;
        box-shadow: 0 10px 24px rgba(13, 34, 62, 0.06);
      }

      .toc {
        position: sticky;
        top: 16px;
        max-height: calc(100dvh - 32px);
        overflow: auto;
        padding: 14px;
      }

      .toc h2 {
        margin: 0 0 10px;
        color: var(--brand);
        font-size: 1rem;
      }

      .toc a {
        display: block;
        text-decoration: none;
        color: #354a64;
        border-radius: 8px;
        padding: 7px 9px;
        font-size: 13px;
      }

      .toc a:hover {
        background: #fff4f3;
        color: #6b1f1f;
      }

      .content {
        padding: 0 0 18px;
      }

      .hero {
        padding: 20px;
        border-bottom: 1px solid var(--line);
        background: linear-gradient(
          160deg,
          #fffdfd 0%,
          #fff3f1 58%,
          #eefbf8 100%
        );
      }

      .eyebrow {
        display: inline-flex;
        align-items: center;
        min-height: 28px;
        padding: 5px 12px;
        border-radius: 999px;
        background: var(--brand-soft);
        color: #7a1f1f;
        font-size: 12px;
        font-weight: 700;
        margin-bottom: 10px;
      }

      h1 {
        margin: 0;
        color: #5f1b1b;
        font-size: clamp(1.45rem, 2.4vw, 2.08rem);
      }

      .subtitle {
        margin: 8px 0 0;
        color: var(--muted);
        line-height: 1.55;
      }

      .hero-layout {
        margin-top: 14px;
        display: grid;
        grid-template-columns: 1.35fr 0.95fr;
        gap: 12px;
      }

      .hero-grid {
        display: grid;
        grid-template-columns: repeat(4, minmax(0, 1fr));
        gap: 10px;
      }

      .metric {
        border: 1px solid #f0cfcc;
        border-radius: 12px;
        background: #fff;
        padding: 10px;
      }

      .metric .k {
        font-size: 11px;
        color: #7c5959;
        margin-bottom: 6px;
        text-transform: uppercase;
        letter-spacing: 0.3px;
      }

      .metric .v {
        font-size: 14px;
        color: #5f1d1d;
        font-weight: 700;
      }

      .hero-visual {
        border: 1px solid #efd0cd;
        border-radius: 14px;
        background: #fff;
        padding: 10px;
        display: grid;
        gap: 8px;
      }

      .hero-visual h3 {
        margin: 0;
        font-size: 0.95rem;
        color: #6f1f1f;
      }

      .hero-visual p {
        margin: 0;
        font-size: 0.84rem;
        color: #5d758c;
      }

      .hero-visual img {
        width: 100%;
        height: 185px;
        object-fit: cover;
        border-radius: 10px;
        border: 1px solid #e2ecf7;
        background: #f8fbff;
      }

      .section {
        padding: 16px 20px;
        border-bottom: 1px solid #edf3fb;
      }

      .section:last-child {
        border-bottom: none;
      }

      .section h2 {
        margin: 0 0 10px;
        color: #6d1f1f;
        font-size: 1.16rem;
      }

      .section p {
        margin: 0;
        color: #314860;
        line-height: 1.56;
      }

      .stack {
        margin-top: 10px;
        display: grid;
        gap: 10px;
      }

      .grid-2 {
        display: grid;
        grid-template-columns: repeat(2, minmax(0, 1fr));
        gap: 10px;
      }

      .grid-3 {
        display: grid;
        grid-template-columns: repeat(3, minmax(0, 1fr));
        gap: 10px;
      }

      .box {
        border: 1px solid var(--line);
        border-radius: 12px;
        padding: 11px 12px;
        background: #fff;
      }

      .box h3 {
        margin: 0 0 7px;
        font-size: 0.97rem;
        color: #1f4061;
      }

      .box p {
        margin: 0;
      }

      .box ul {
        margin: 0 0 0 17px;
        padding: 0;
      }

      .box li {
        margin: 4px 0;
        color: #304860;
      }

      .table {
        margin-top: 8px;
        width: 100%;
        border-collapse: collapse;
        border-radius: 12px;
        border: 1px solid var(--line);
        overflow: hidden;
      }

      .table th,
      .table td {
        padding: 10px;
        text-align: left;
        font-size: 14px;
        border-bottom: 1px solid #e8eff8;
        vertical-align: top;
      }

      .table th {
        background: #fff4f3;
        color: #6f1f1f;
      }

      .table tr:last-child td {
        border-bottom: none;
      }

      .chips {
        margin-top: 8px;
        display: flex;
        gap: 8px;
        flex-wrap: wrap;
      }

      .chip {
        display: inline-flex;
        align-items: center;
        min-height: 30px;
        padding: 4px 10px;
        border-radius: 999px;
        border: 1px solid #d8e4f2;
        background: #f8fbff;
        color: #254764;
        font-size: 13px;
        font-weight: 600;
      }

      .callout {
        margin-top: 10px;
        border-left: 4px solid #0f766e;
        border-radius: 10px;
        background: var(--teal-soft);
        color: #175358;
        padding: 10px 12px;
      }

      .callout.warn {
        border-left-color: #b66a00;
        background: var(--warn-soft);
        color: #7c5b1d;
      }

      .callout.alert {
        border-left-color: #b91c1c;
        background: var(--danger-soft);
        color: #6d2222;
      }

      .flow {
        margin-top: 10px;
        display: grid;
        gap: 9px;
      }

      .step {
        border: 1px solid #d5e3f4;
        border-radius: 12px;
        padding: 10px 11px;
        background: #f9fcff;
      }

      .step strong {
        color: #6d1f1f;
      }

      .arrow {
        width: 30px;
        height: 30px;
        margin: 0 auto;
        border-radius: 999px;
        border: 1px solid #c9d8ec;
        background: #f6fbff;
        color: #456887;
        font-weight: 900;
        display: grid;
        place-items: center;
        line-height: 1;
      }

      .diagram-card {
        margin-top: 10px;
        border: 1px solid #d8e4f2;
        border-radius: 12px;
        background: #fbfdff;
        padding: 11px;
      }

      .diagram-title {
        margin: 0 0 8px;
        font-size: 0.9rem;
        color: #1d3f62;
        font-weight: 700;
      }

      .diagram-card svg {
        width: 100%;
        height: auto;
        display: block;
      }

      .image-grid {
        margin-top: 10px;
        display: grid;
        grid-template-columns: repeat(3, minmax(0, 1fr));
        gap: 10px;
      }

      .image-card {
        border: 1px solid #d8e4f2;
        border-radius: 12px;
        background: #fff;
        padding: 8px;
      }

      .image-card img {
        width: 100%;
        height: 175px;
        object-fit: cover;
        border-radius: 8px;
        border: 1px solid #e4edf7;
        background: #f9fcff;
      }

      .image-card .cap {
        margin-top: 7px;
        font-size: 12px;
        color: #435b74;
      }

      .refs a {
        color: #145aa9;
        text-decoration: none;
        word-break: break-word;
      }

      .refs a:hover {
        text-decoration: underline;
      }

      @media (max-width: 1040px) {
        .wrap {
          grid-template-columns: 1fr;
        }

        .toc {
          position: static;
          max-height: none;
        }

        .hero-layout {
          grid-template-columns: 1fr;
        }

        .hero-grid {
          grid-template-columns: repeat(2, minmax(0, 1fr));
        }

        .image-grid {
          grid-template-columns: repeat(2, minmax(0, 1fr));
        }
      }

      @media (max-width: 760px) {
        .grid-2,
        .grid-3,
        .hero-grid,
        .image-grid {
          grid-template-columns: 1fr;
        }
      }
    </style>
  </head>
  <body>
    <div class="wrap">
      <aside class="panel toc">
        <h2>On This Page</h2>
        <a href="#what-are-arrhythmias">1. What Are Arrhythmias?</a>
        <a href="#electrophysiology-refresher"
          >2. Electrophysiology Refresher</a
        >
        <a href="#major-arrhythmias-tested">3. Major Arrhythmias Tested</a>
        <a href="#atrial-fibrillation">4. Atrial Fibrillation (AF)</a>
        <a href="#stroke-prevention-in-af">5. Stroke Prevention in AF</a>
        <a href="#ventricular-arrhythmias">6. Ventricular Arrhythmias</a>
        <a href="#bradyarrhythmias">7. Bradyarrhythmias</a>
        <a href="#vaughan-williams-summary">8. Vaughan-Williams Summary</a>
        <a href="#management-recap-drill">Recap Drill</a>
        <a href="#exam-traps">9. Common Exam Traps</a>
        <a href="#quick-revision">10. Quick Revision Summary</a>
      </aside>

      <article class="panel content">
        <header class="hero">
          <span class="eyebrow">Cardiovascular Disorders</span>
          <h1>Arrhythmias</h1>
          <p class="subtitle">
            Clinical Overview and Exam Mastery Guide for atrial fibrillation,
            antiarrhythmic classes, ventricular arrhythmias, stroke prevention,
            and bradyarrhythmia management.
          </p>

          <div class="hero-layout">
            <div class="hero-grid">
              <div class="metric">
                <div class="k">Rhythm Types</div>
                <div class="v">Tachy, brady, irregular</div>
              </div>
              <div class="metric">
                <div class="k">AF Core Plan</div>
                <div class="v">Rate + rhythm + anticoagulation</div>
              </div>
              <div class="metric">
                <div class="k">VT Priority</div>
                <div class="v">Urgent rhythm stabilization</div>
              </div>
              <div class="metric">
                <div class="k">Drug Class System</div>
                <div class="v">Vaughan-Williams I to IV</div>
              </div>
            </div>

            <div class="hero-visual">
              <h3>Real ECG and Conduction Visual</h3>
              <img
                src="images/ecg-conduction.png"
                alt="ECG and Cardiac Conduction System"
                loading="lazy"
                referrerpolicy="no-referrer"
              />
              <p>
                Conduction pathway anatomy anchors rate/rhythm pharmacology
                decisions.
              </p>
            </div>
          </div>
        </header>

        <section class="section" id="what-are-arrhythmias">
          <h2>1. What Are Arrhythmias?</h2>
          <p>
            Arrhythmias are disorders of heart rhythm caused by abnormalities in
            impulse generation, impulse conduction, or both.
          </p>
          <div class="chips">
            <span class="chip">Tachyarrhythmias</span>
            <span class="chip">Bradyarrhythmias</span>
            <span class="chip">Irregular rhythms</span>
            <span class="chip">Benign to life-threatening spectrum</span>
          </div>
        </section>

        <section class="section" id="electrophysiology-refresher">
          <h2>2. Basic Electrophysiology Refresher</h2>
          <p>
            Conduction pathway: SA node -> AV node -> Bundle of His -> Purkinje
            fibers.
          </p>
          <div class="grid-2 stack">
            <div class="box">
              <h3>Drug Targets</h3>
              <ul>
                <li>Sodium channels</li>
                <li>Potassium channels</li>
                <li>Calcium channels</li>
                <li>Beta receptors</li>
              </ul>
            </div>
            <div class="box">
              <h3>Exam Logic</h3>
              <ul>
                <li>
                  Node-focused drugs affect AV conduction and rate control
                </li>
                <li>Channel blockers alter depolarization/repolarization</li>
                <li>Misapplied class choice can be proarrhythmic</li>
              </ul>
            </div>
          </div>
        </section>

        <section class="section" id="major-arrhythmias-tested">
          <h2>3. Major Arrhythmias Tested</h2>
          <div class="chips">
            <span class="chip">Atrial fibrillation (AF)</span>
            <span class="chip">Atrial flutter</span>
            <span class="chip">SVT</span>
            <span class="chip">Ventricular tachycardia (VT)</span>
            <span class="chip">Ventricular fibrillation (VF)</span>
            <span class="chip">Bradyarrhythmias</span>
          </div>

          <div class="image-grid">
            <figure class="image-card">
              <img
                src="https://upload.wikimedia.org/wikipedia/commons/3/32/ECG_Atrial_Fibrillation.jpg"
                alt="ECG strip showing atrial fibrillation"
                loading="lazy"
                referrerpolicy="no-referrer"
              />
              <figcaption class="cap">
                Atrial fibrillation ECG example
              </figcaption>
            </figure>
            <figure class="image-card">
              <img
                src="https://upload.wikimedia.org/wikipedia/commons/4/4b/ECG-atrial_flutter.jpg"
                alt="ECG strip showing atrial flutter"
                loading="lazy"
                referrerpolicy="no-referrer"
              />
              <figcaption class="cap">Atrial flutter ECG example</figcaption>
            </figure>
            <figure class="image-card">
              <img
                src="https://upload.wikimedia.org/wikipedia/commons/c/c4/Electrocardiogram_of_Ventricular_Tachycardia.png"
                alt="ECG strip showing ventricular tachycardia"
                loading="lazy"
                referrerpolicy="no-referrer"
              />
              <figcaption class="cap">
                Ventricular tachycardia ECG example
              </figcaption>
            </figure>
          </div>
        </section>

        <section class="section" id="atrial-fibrillation">
          <h2>4. Atrial Fibrillation (AF)</h2>
          <p>
            AF is the most common arrhythmia, classically irregularly irregular,
            with no distinct P waves. Core risks include stroke and heart
            failure.
          </p>

          <div class="callout">
            Management goals: rate control, rhythm control, and stroke
            prevention.
          </div>

          <div class="stack">
            <div class="box">
              <h3>A. Rate Control</h3>
              <div class="grid-2">
                <div>
                  <p><strong>Beta Blockers</strong></p>
                  <p>Examples: metoprolol, atenolol.</p>
                  <ul>
                    <li>
                      MOA: beta1 blockade slows AV nodal conduction and HR
                    </li>
                    <li>Side effects: bradycardia, hypotension, fatigue</li>
                    <li>Contra: severe bradycardia, cardiogenic shock</li>
                  </ul>
                </div>
                <div>
                  <p><strong>Non-DHP CCB</strong></p>
                  <p>Diltiazem, verapamil.</p>
                  <ul>
                    <li>MOA: L-type calcium channel block at AV node</li>
                    <li>
                      Side effects: bradycardia, hypotension, constipation
                      (verapamil)
                    </li>
                    <li>Contra: HFrEF, severe hypotension</li>
                  </ul>
                </div>
              </div>

              <div class="stack">
                <div class="box">
                  <h3>Digoxin</h3>
                  <ul>
                    <li>
                      MOA: Na/K ATPase inhibition with increased vagal tone and
                      slower AV conduction
                    </li>
                    <li>Role: rate control; does not improve survival</li>
                    <li>
                      Side effects: nausea, visual disturbances, arrhythmias
                    </li>
                    <li>Toxicity worsens with hypokalemia</li>
                  </ul>
                </div>
              </div>
            </div>

            <div class="box">
              <h3>B. Rhythm Control</h3>
              <p>Used when symptoms persist or rate-control strategy fails.</p>
              <div class="grid-2 stack">
                <div class="box">
                  <h3>Amiodarone (Class III)</h3>
                  <ul>
                    <li>
                      MOA: potassium channel block plus sodium, calcium, and
                      beta receptor effects
                    </li>
                    <li>Benefit: effective in AF and VT</li>
                    <li>
                      Major side effects: pulmonary fibrosis, thyroid
                      dysfunction, liver toxicity, photosensitivity, corneal
                      deposits
                    </li>
                    <li>
                      Contra: severe sinus-node dysfunction, relative caution in
                      pregnancy
                    </li>
                  </ul>
                </div>
                <div class="box">
                  <h3>Class IC (Flecainide, Propafenone)</h3>
                  <ul>
                    <li>
                      MOA: sodium channel blockade slows conduction velocity
                    </li>
                    <li>Proarrhythmic risk in structural disease</li>
                    <li>Contra: structural heart disease and post-MI state</li>
                  </ul>
                </div>
              </div>
            </div>
          </div>
        </section>

        <section class="section" id="stroke-prevention-in-af">
          <h2>5. Stroke Prevention in AF</h2>
          <p>
            Use CHA2DS2-VASc risk scoring. Elevated risk supports
            anticoagulation.
          </p>
          <div class="grid-2 stack">
            <div class="box">
              <h3>DOACs</h3>
              <p>Apixaban, rivaroxaban, dabigatran, edoxaban.</p>
              <ul>
                <li>MOA: direct factor Xa or thrombin inhibition</li>
                <li>Side effects: bleeding</li>
                <li>
                  Contra: active bleeding, severe renal impairment (agent
                  dependent)
                </li>
              </ul>
            </div>
            <div class="box">
              <h3>Warfarin</h3>
              <ul>
                <li>
                  MOA: inhibits vitamin K-dependent factors II, VII, IX, X
                </li>
                <li>Monitoring: INR target usually 2 to 3</li>
                <li>Side effects: bleeding, rare skin necrosis</li>
                <li>Contra: pregnancy</li>
              </ul>
            </div>
          </div>
        </section>

        <section class="section" id="ventricular-arrhythmias">
          <h2>6. Ventricular Arrhythmias</h2>
          <p>
            Ventricular tachycardia is potentially life-threatening and requires
            urgent management.
          </p>
          <div class="grid-2 stack">
            <div class="box">
              <h3>Amiodarone</h3>
              <p>Common first-line option in stable VT.</p>
            </div>
            <div class="box">
              <h3>Lidocaine (Class IB)</h3>
              <ul>
                <li>
                  MOA: sodium-channel block with shortened action potential
                </li>
                <li>Use: ischemic VT contexts</li>
                <li>Side effects: CNS toxicity, seizures at high doses</li>
              </ul>
            </div>
          </div>
        </section>

        <section class="section" id="bradyarrhythmias">
          <h2>7. Bradyarrhythmias</h2>
          <div class="grid-2">
            <div class="box">
              <h3>Atropine First-Line</h3>
              <ul>
                <li>MOA: muscarinic blockade increases heart rate</li>
                <li>Side effects: dry mouth, urinary retention</li>
              </ul>
            </div>
            <div class="box">
              <h3>Escalation</h3>
              <ul>
                <li>
                  Persistent severe symptomatic bradycardia may require
                  pacemaker
                </li>
              </ul>
            </div>
          </div>
        </section>

        <section class="section" id="vaughan-williams-summary">
          <h2>8. Vaughan-Williams Classification Summary</h2>
          <table class="table">
            <thead>
              <tr>
                <th>Class</th>
                <th>Target</th>
                <th>Examples</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>Class I</td>
                <td>Sodium channel blockers</td>
                <td>Flecainide, propafenone, lidocaine</td>
              </tr>
              <tr>
                <td>Class II</td>
                <td>Beta blockers</td>
                <td>Metoprolol, atenolol</td>
              </tr>
              <tr>
                <td>Class III</td>
                <td>Potassium channel blockers</td>
                <td>Amiodarone</td>
              </tr>
              <tr>
                <td>Class IV</td>
                <td>Calcium channel blockers</td>
                <td>Diltiazem, verapamil</td>
              </tr>
            </tbody>
          </table>
        </section>

        <section class="section" id="management-recap-drill">
          <h2>Management Recap Drill</h2>
          <div class="flow">
            <div class="step">
              <strong>AF Step 1:</strong> Determine hemodynamic stability
            </div>
            <div class="arrow" aria-hidden="true">&#8595;</div>
            <div class="step">
              <strong>AF Step 2:</strong> Rate control with beta blocker or
              non-DHP CCB
            </div>
            <div class="arrow" aria-hidden="true">&#8595;</div>
            <div class="step">
              <strong>AF Step 3:</strong> Consider rhythm control if
              symptomatic/persistent
            </div>
            <div class="arrow" aria-hidden="true">&#8595;</div>
            <div class="step">
              <strong>AF Step 4:</strong> Assess stroke risk and anticoagulate
              when indicated
            </div>
            <div class="arrow" aria-hidden="true">&#8595;</div>
            <div class="step">
              <strong>VT/Brady add-on:</strong> VT uses amiodarone/lidocaine;
              symptomatic bradycardia uses atropine first
            </div>
          </div>

          <div class="diagram-card">
            <p class="diagram-title">Visual Algorithm Placeholder</p>
            <p>
              [Insert Atrial Fibrillation and Antiarrhythmic Classification
              Flowchart Here During UI Integration]
            </p>
          </div>
        </section>

        <section class="section refs">
          <h2>Guideline References</h2>
          <div class="grid-2">
            <div class="box">
              <h3>ACC/AHA/HRS Guideline for Atrial Fibrillation</h3>
              <a
                href="https://www.acc.org/guidelines"
                target="_blank"
                rel="noopener"
              >
                https://www.acc.org/guidelines
              </a>
            </div>
            <div class="box">
              <h3>ACC/AHA Guideline for Ventricular Arrhythmias</h3>
              <a
                href="https://www.acc.org/guidelines"
                target="_blank"
                rel="noopener"
              >
                https://www.acc.org/guidelines
              </a>
            </div>
          </div>

          <div class="stack">
            <div class="box">
              <h3>Image Attributions (Wikimedia Commons)</h3>
              <ul>
                <li>Cardiac Conduction System - Cypressvine, CC BY-SA 4.0</li>
                <li>ECG Atrial Fibrillation - Ewingdo, CC BY-SA 4.0</li>
                <li>ECG-atrial flutter - Ciernik M, CC BY-SA 4.0</li>
                <li>
                  Electrocardiogram of Ventricular Tachycardia - Karthik Sheka,
                  CC BY-SA 2.5
                </li>
              </ul>
            </div>
          </div>
        </section>

        <section class="section" id="exam-traps">
          <h2>9. Common Exam Traps</h2>
          <div class="stack">
            <div class="callout alert">
              Non-DHP calcium channel blockers are contraindicated in HFrEF.
            </div>
            <div class="callout alert">
              Amiodarone can cause multi-organ toxicity.
            </div>
            <div class="callout alert">
              Class IC agents are contraindicated in structural heart disease.
            </div>
            <div class="callout alert">Digoxin does not reduce mortality.</div>
            <div class="callout alert">
              AF management always includes stroke-risk assessment.
            </div>
          </div>
        </section>

        <section class="section" id="quick-revision">
          <h2>10. Quick Revision Summary</h2>
          <div class="grid-2">
            <div class="box">
              <h3>Must Remember</h3>
              <ul>
                <li>
                  AF = rate control + rhythm strategy + anticoagulation decision
                </li>
                <li>Amiodarone is a broad multi-channel blocker</li>
                <li>DOACs are preferred over warfarin in many AF scenarios</li>
                <li>VT needs urgent rhythm-focused treatment</li>
                <li>Symptomatic bradycardia -> atropine first</li>
              </ul>
            </div>
            <div class="box">
              <h3>Practice Questions Placeholder</h3>
              <ul>
                <li>Topic: Arrhythmias</li>
                <li>
                  Subtopics: atrial fibrillation, anticoagulation,
                  antiarrhythmic classes, ventricular tachycardia,
                  bradyarrhythmias
                </li>
              </ul>
            </div>
          </div>
        </section>
      </article>
    </div>
  </body>
</html>
